Stage 0 | Stage 1 | Stage 2 | Stage 3 | Stage 4 | ||||||
---|---|---|---|---|---|---|---|---|---|---|
n (% total with OCT) | 50 | (42.0%) | 56 | (47.1%) | 9 | (7.6%) | 3 | (2.5%) | 1 | (0.8%) |
Timing of OCT/ERM post surgery (days), mean (SD) | 439.4 | (368.1) | 392.5 | (199.1) | 263.7 | (184.8) | 459.7 | (692.0) | 207.0 | (NA) |
Central foveal thickness (um), mean (SD) | 245.9 | (46.1) | 258.3 | (44.5) | 345.6+ | (45.1) | 433.7+ | (60.5) | 614.0+ | (NA) |
Ectopic inner foveal layer thickness (um), mean (SD) | 7.5 | (22.9) | 12.1 | (26.0) | 27.4 | (38.0) | 161.3+ | (40.1) | 362.0+ | (NA) |
Outer nuclear layer thickness (um), mean (SD) | 125.9 | (36.0) | 142.9 | (36.9) | 200.6+ | (41.9) | 205.7+ | (13.9) | 177.0+ | (NA) |
Ellipsoid zone disruption, n (% of type) | 3 | (6.0%) | 4 | (7.1%) | 0 | (0.0%) | 0 | (0.0%) | 1 | (100.0%) |
Intraretinal cysts, n (% of type) | 6 | (12.0%) | 14 | (25.0%) | 6 | (66.7%) | 2 | (66.7%) | 1 | (100.0%) |
Subretinal fluid, n (% of type) | 0 | (0.0%) | 2 | (3.6%) | 1 | (11.1%) | 0 | (0.0%) | 0 | (0.0%) |
Mean visual acuity, LogMAR (SD) | 0.3 | (0.4) | 0.2 | (0.3) | 0.2 | (0.2) | 0.9 | (0.9) | 0.6 | (NA) |
Mean snellen visual acuity | 20/40 | 20/30 | 20/30 | 20/160* | 20/80* |